Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

Background We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition
with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a …

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged
non-small-cell lung cancer (NSCLC) is not known. We assessed the …

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical
responses in a sizable minority of cancer patients. We found that primary resistance to ICIs …

The development of human cancer is a multistep process characterized by the accumulation
of genetic and epigenetic alterations that drive or reflect tumour progression. These …

Background Adjuvant cisplatin-based chemotherapy improves survival among patients with
completely resected non–small-cell lung cancer, but there is no validated clinical or biologic …

Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …

The AACR Project GENIE is an international data-sharing consortium focused on generating
an evidence base for precision cancer medicine by integrating clinical-grade cancer …

Purpose: While immune checkpoint inhibitors are disrupting the management of patients with
cancer, anecdotal occurrences of rapid progression (ie, hyperprogressive disease or HPD) …

Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis 1 ,
2 , 3 . We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an …